Hoth Therapeutics ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth's BioLexa Platform. Laidlaw & Co (UK) Ltd. ("Laidlaw") in New York served as the sole placement agent.

Robb Knie, Hoth CEO stated, "We are extremely pleased to have completed this equity financing. We look forward to continuing to build value for our shareholders and furthering the development of the BioLexa Platform. We are appreciative of our initial investment by Spherix (NASDAQ: SPEX) and the completion of this funding by Laidlaw. We thank our investors for the confidence they have shown in us."

James Ahern, Laidlaw Managing Partner and Head of Capital Markets commented, "Laidlaw is pleased to have acted as the sole placement agent for Hoth and we look forward to future milestones and inflection points."

About Hoth Therapeutics Incorporated
Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

About Laidlaw & Co. (UK) Ltd.
Laidlaw & Company (UK) Ltd, founded in 1842, is a relationship driven international investment bank, providing wealth management services, capital raising, mergers & acquisitions advisory, research and corporate access to clients on a global level. Headquartered in New York City and United Kingdom, Laidlaw maintains eight offices across the United States and London, England with over 150 employees firm wide. Laidlaw also offers personalized investment advice and skillful execution to private and public institutions, as well as high net worth individual investors. The firm is a FINRA, MSRB and SIPC registered company.